Celltrion Reports Results of CT-P59 in P-I Study for COVID-19

November 9, 2020 Auto Bot 2020, Celltrion, Clinical, Clinical Trials, Conference, CT-P59, P-I, Presents, results, Trial 0

Shots:

  • The P-I clinical trial involves assessing CT-P59 (20/40/80 mg/kg) vs PBO in 18 patients with mild symptoms of SARS-COV-2 infection who were randomized into 3 cohorts
  • Results: patients demonstrated a 44% reduction in mean clinical recovery time, while no patients required hospitalization or antiviral therapy
  • Celltrion has submitted the IND application for the clinical trial globally & plans to conduct global P-II & P-III trials including Korea. Additionally, Celltrion has also initiated a post-exposure prophylaxis study assessing CT-P59 as a protective treatment, by investigating the efficacy of the treatment in those who have been in contact with confirmed SARS-CoV-2 infected patients

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Medical News Today

The post Celltrion Reports Results of CT-P59 in P-I Study for COVID-19 first appeared on PharmaShots.